# SWOG CANCER RESEARCH NETWORK







# Fall 2019 Meeting Plenary II Disclosure Information

Charles Blanke, MD, FACP, FASCO: None

Don Dizon, MD, FACP, FASCO: None

Mark Lewis, MD: None

Olufunmilayo Olopade, MD, FACP: Co-founder and stockholder of

CancerIQ; Scientific advisory board member of Tempus

Bonnie Spring, PhD: None





# Plenary II Agenda

- News & Accomplishments
- Farewells and Welcomes
- Young Investigator Training Course
- SEED Award Winner
- Plenary Speakers:
  - Don Dizon, MD
  - Mark Lewis, MD
  - Bonnie Spring, PhD
  - Harry E. Hynes Memorial Lecture: Olofunmilayo Olopade, MD





# News & Accomplishments







Francis S. Collins @ @NIHDirector · Sep 18

New #NIH-funded study finds that ~half of phase 3 #clinicaltrials by @theNCI's SWOG Cancer Research Network were associated w/ advancing patient standard of care via clinical care guidelines or drug approvals.



**OF 182 PHASE 3 CLINICAL TRIALS** 

BETWEEN **1980** AND **2017** 

INFLUENCED GUIDELINE CARE OD NEW DDIIC ADDDOVAL

Study quantifies impact of NIH-sponsored trials on clinical cancer Researchers found trials add value regardless of whether findings were positive or negative.

⊗ nih.gov

 $\Omega$  2

↑7 26

**9** 61

ıŤ,



Dr. Doug Lowy ♥ @NCIDrDougLowy · Sep 18

This study from @SWOG provides evidence for what we would expect to see: cancer clinical trials conducted in @theNCI's National Clinical Trials Network play a critical role in identifying effective treatment options for patients.



NCI Media Relations ② @NCIMedia · Sep 18



A new study shows nearly half of phase 3 cancer clinical trials carried out by @theNCI -sponsored SWOG Cancer Research Network, one of 5 groups in NCI's National Clinical Trials Network, were associated with clinical care guidelines or new drug approvals bit.ly/2LAgYEi

**OF 182 PHASE 3 CLINICAL TRIALS** 

BETWEEN **1980** AND **2017** 

INFLUENCED GUIDELINE CARE OR **NEW DRUG APPROVALS** 

Source: Unger JM et al. JAMA Netw Open. doi:10.1001/jamanetworkopen.2019.10593









\*Industry-run \$1.73 billion







# **Our NCI Budgets**

Good to excellent news

NCTN, NCORP, and stats budgets all increased





## NCI Funding March 2019-2025

#### **NCTN**

Category	Grant Year 5 PREVIOUS GRANT CYCLE	Grant Year 6 NEW GRANT CYCLE	Difference
Total Cost	\$11,571,699	\$12,139,981	+568,282

### **NCORP**

Category	Grant Year 5 PREVIOUS GRANT CYCLE	Grant Year 6 NEW GRANT CYCLE	Difference
Total Cost	\$5,961,114	\$6,737,472	+776,358





# **NCTN Site Payments**

Accrual Type	Main Member/Affiliate & Standard NCORP Rate	LAPS & High-Performing NCORP Rate
Screening on Study*	\$600 (Variable)	\$600 (Variable)
Treatment Intervention Non-IND study	\$2,700	\$4,300
Treatment Intervention IND study (Non-CTEP)	\$3,000	\$4,600
Treatment Intervention IND study (CTEP)	\$3,600	\$5,200
Imaging (base accrual)	\$1,200	\$1,200
Biospecimen Collections	Variable \$500/pt/trial	Variable \$500/pt/trial





# **NCORP Site Payments**

Accrual Type	Main member/Affiliate, LAPS & Standard NCORP Rate	High-Performing NCORP Rate
Screening on Study*	Variable	Variable
Cancer Control/Prevention/ QOL Intervention	\$3,000	\$5,000
Biospecimen Collections	Variable	Variable







### **ImmunoMATCH**











### ImmunoMATCH Details

- Master chaired by Drs. Ken Grossman and Katerina Politi
  - SWOG portfolio: Dr. Siwen Hu-Lieskovan
- Variety of eligible solid tumors
- First- and second-line therapies
- Emphasis on combinations
- Launching in 2020





### **SWOG Latin America Initiative**

### 5 NCI studies close to activation



- S1802
- S1714
- S1827
- BR003
- InPACT



# July 29 Plain Language Workshop









## Plain Language in the NCTN

- No group currently employs a plain language writer
- Printable/shareable trial summaries posted on SWOG.org
- Our thanks to The Hope Foundation for Cancer Research





# **Community Advocate Program**

- Brings a new "style" of advocate to SWOG
- Representation from those with a different perspective
- Helps with diversity of trial participants, including accrual tactics in special populations





# **Community Advocates**











# 30 Years of Leading SWOG!









# Farewells & Welcomes







# **Outgoing ORP Chair**



Keisha Humphries, RN, BSN, OCN







# **Incoming ORP Chair**



Connie Szczepanek, RN, BSN, CCRP







# **Incoming Melanoma Chair**



Kenneth Grossmann, MD







# Incoming Immunotherapy Co-Chair



Siwen Hu-Lieskovan, MD, PhD







# THE HOPE FOUNDATION FOR CANCER RESEARCH

SUPPORTING SWOG CANCER RESEARCH NETWORK

# 2019 Young Investigators









## 2019 SWOG Young Investigators

Arya Amini, MD

Jose Rodrigo Espinosa Fernandez, MD

Leah Ferrucci, PhD, MPH

Brian Hess, MD

Benjamin Maughan, MD, PharmD

Jing (Christine) Ye, MD

City of Hope

Instit. Nacional de Cancerologia

Yale School of Public Health

Medical Univ. of South Carolina

**Huntsman Cancer Institute** 

University of Michigan







## 2019 SEED Award

Dan L. Hertz, PharmD, PhD
University of Michigan College of Pharmacy

Siu-Fun Wong, PharmD Chapman University

"Prospective Drug-Drug Interaction Screening in SWOG Clinical Trials"





# **Plenary Speaker**



Don Dizon, MD







# **Plenary Speaker**



Mark Lewis, MD







# **Plenary Speaker**



**Bonnie Spring, PhD** 







# Harry Hynes Memorial Lecturer




Olufunmilayo Olopade, MD
















































# SWOG CANCER RESEARCH NETWORK





